科学家新进研究成功一种药物可以与肿瘤细胞生成的血管生长因子反应而起到抑制肿瘤细胞生长的效果。这种叫做bevacizumab的药物已获FDA批准生产。

肿瘤细胞分泌产生很多不同量的各种血管新生因子。缺氧诱导因子1介导基因转录编码血管新生因子。由于氧利用率低使得这种缺氧诱导因子水平在很多肿瘤中都很高，然后随着相关基因表达使致癌基因活化，导致肿瘤抑制基因失活。

bevacizumab是一种对抗血管内皮生长因子（VEGF）的人类单克隆抗体，可以通过抑制血管新生来治疗癌症。

原始出处：

NEJM,Volume 358:2066-2067,May 8, 2008  Number 19,Gregg L. Semenza

A New Weapon for Attacking Tumor Blood Vessels


Gregg L. Semenza, M.D., Ph.D.

The approval by the Food and Drug Administration of bevacizumab,a humanized monoclonal antibody against vascular endothelialgrowth factor (VEGF),1 sparked enormous excitement among oncologists.Bevacizumab, the first cancer therapy that acts by blockingangiogenesis, is the result of the successful translation ofpioneering work by the late Judah Folkman and his colleagues,who proposed that vascularization is essential for the growthof clinically relevant invasive carcinomas. A recent study byFischer and colleagues2 indicates that a monoclonal antibodyagainst another angiogenic protein, placental growth factor(PlGF), may also be a useful antiangiogenic therapy for cancerin humans.